Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYL719 with Capecitabine and Radiation in Rectal Cancer
NCT02550743Phase 1Terminated
- Start
- Jun 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpelisib in rectal cancer (4 arms). Primary endpoint: Maximum Tolerated Dose of BYL719 at 6 weeks. Started Jun 2016; status: terminated.
02
Drugs
alpelisib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02550743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550743.